Evaluating AMX0114 for treating ALS in adults

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This Phase I clinical trial is a placebo-controlled study aimed at assessing the safety, tolerability, pharmacokinetics, and pharmacodynamics of the investigational drug AMX0114 in adult participants diagnosed with amyotrophic lateral sclerosis (ALS). Participants will receive AMX0114 via intrathecal injection, and the study will monitor various health parameters, including adverse events and biomarkers related to ALS. The goal is to determine how well the drug is tolerated and its potential effects on the disease.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Ability to understand the purpose and risks of this study, willingness to comply with the study and to provide informed consent in accordance with local laws and regulations.
2. Male or female, at least 18 years of age.
3. Diagnosis of clinically definite or clinically probable ALS, made by a physician who is experienced with management of ALS.
4. Time since onset of first symptom of ALS should be \<24 months prior to beginning the study. Date of ALS symptom onset is defined as the onset of weakness (in the limbs, bulbar region, or trunk).
5. If the participant is to be treated with riluzole and/or edaravone before or during the trial, then treatment must be previously started and maintained at a stable regimen for at least 30 days prior to starting the study and through the end of the study.
6. Women of childbearing potential (e.g., not post-menopausal for at least one year or surgically sterile) must agree to use an acceptable birth control method for the duration of the trial and 60 days after the last dose of Study Drug or be of non-childbearing potential.
7. Female participants or female partners of male participants must not be pregnant or plan to become pregnant for the duration of the trial and for up to 90 days after the last dose of Study Drug.
8. Male participants must agree to abstain from sperm donation for the duration of the trial and practice contraception with a female partner, for at least 90 days after last dose of Study Drug.

Exclusion Criteria:

1. Presence of tracheostomy or permanent assisted ventilation.
2. SVC less than 65%.
3. Abnormal liver function defined as aspartate aminotransferase and/or alanine aminotransferase \> 3 times the upper limit of normal (ULN) and/or total bilirubin \> 1.5 times the ULN (obtained within 4 weeks of first dose) except when a result of Gilbert syndrome.
4. Abnormal renal function defined as estimated glomerular filtration rate (eGFR) \< 60 mL/min/1.73m2.
5. Other laboratory abnormalities, including abnormalities in platelet count, international normalized ratio, prothrombin time, and activated partial thromboplastin time.
6. Pregnant women (confirmed by a pregnancy test within 7 days prior to first dose) or women currently breastfeeding.
7. Current or previous clinically significant, unstable medical condition (other than ALS), that in the opinion of the Investigator could affect a participant's safety or ability to comply with the study.
8. Significant abnormalities in physical/neurological examination, vital signs, or electrocardiogram (ECG), which in the opinion of the Investigator could affect the safety of the participant.
9. Presence of unstable psychiatric disease, cognitive impairment, dementia or substance abuse that could affect the participant's ability to provide informed consent or comply with study procedures.
10. Current or previous enrollment in another trial involving use of an investigational therapy, in most cases within 30 days after the last dose of the study drug, prior to starting this study.
11. Current or previous treatment with small interfering ribonucleic acid, stem cell therapy, any ASO or gene therapy.
12. Any contraindications for lumbar puncture or repeated intrathecal injection and/or underlying disorders that could be affected by intrathecal injections.
13. Prior severe reaction or known hypersensitivity to any part of the Study Drug.

Where it's running

• University of California, San Diego
  La Jolla, California, United States Recruiting
• Georgetown University Hospital Pasquerilla Healthcare Center
  Washington D.C., District of Columbia, United States Recruiting
• University of Florida
  Gainesville, Florida, United States Recruiting
• Mayo Clinic in Florida
  Jacksonville, Florida, United States Recruiting
• Orlando Regional Medical Center, Orlando Health Neuroscience Institute
  Orlando, Florida, United States Recruiting
• Massachusetts General Hospital, Healey & AMG Center for ALS
  Boston, Massachusetts, United States Recruiting

Study contacts

• Study coordinator: Medical Director, Amylyx
• Email: clinicaltrials@amylyx.com
• Phone: 857-320-6200

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Decoding Mandarin speech features from brain-surface signals

  This project will try to decode imagined Mandarin speech, including lexical tones, from high-density brain-surface (ECoG) signals in adult patients who are having clinically indicated cortical electrode placement.

  Recruiting Second Affiliated Hospital, Zhejiang University, School of Medicine · Hangzhou, Zhejiang · NCT07460037

• At-home cortico-spinal tDCS for ALS.

  This treatment tests whether daily at-home cortico-spinal tDCS can slow nerve damage and symptoms in adults with early ALS.

  Recruiting University of Trieste · Trieste, Trieste · NCT07006571

• Cell therapy using induced pluripotent stem cells for ALS treatment

  This study is testing a new cell therapy using stem cells to see if it can safely help people with ALS feel better.

  Recruiting Shanghai East Hospital · Shanghai, Shanghai Municipality · NCT06765564

• Multicenter study using MRI to identify biomarkers in ALS patients

  This study is trying to see if brain scans and blood tests can help track how ALS changes over time in patients compared to healthy people.

  Recruiting at 3 sites University of Minnesota · Gainesville, Florida and 2 other locations · NCT06735014

• Using a brain-computer interface to help people with tetraplegia communicate

  This study is testing a new brain-computer interface to help people with tetraplegia communicate more easily using a tablet.

  Recruiting Massachusetts General Hospital · Boston, Massachusetts · NCT06511934

• Advancing genomic medicine using electronic health records

  This study is trying to see if using electronic health records and helpful reminders can get more patients tested for genetic conditions in a way that doctors can easily use.

  Recruiting University of Pennsylvania · Philadelphia, Pennsylvania · NCT06377033

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.